ASH 2022 Conference Coverage
ASH 2022 Phase 3 EMagine/CARTITUDE-6 Trial: DVRd Followed by either Cilta-Cel or ASCT in Transplant-Eligible NDMM
By
ASH 2022 Conference Coverage
FEATURING
Pieter Sonneveld
By
ASH 2022 Conference Coverage
FEATURING
Pieter Sonneveld
Login to view comments.
Click here to Login